Tirofiban
Tirofiban is a non-peptide glycoprotein IIb/IIIa (αIIbβ3 integrin) receptor antagonist that blocks the binding of fibrinogen, von Willebrand factor, and other adhesive proteins to activated platelet receptors, preventing platelet aggregation and thrombus formation. It is used intravenously in combination with heparin for the management of acute coronary syndromes (unstable angina and NSTEMI) and percutaneous coronary intervention. Its reversible binding and short duration of action allow rapid recovery of platelet function after discontinuation.
Berat Molekul
440,6000 g/mol
LogP
1,40
TPSA
113,00 Ų
Lipinski RO5
Lulus
Area Terapeutik
Mekanisme Kerja
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Struktur 2D
Cite this structure
Embed this structure
SMILES
CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(=O)O
InChI
InChI=1S/C22H36N2O5S/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26)/t21-/m0/s1
Molecular Formula
C22H36N2O5S
HBD / HBA
3 / 7
Ikatan yang Dapat Dirotasi
14
Atom Berat
30
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Pertanyaan yang Sering Diajukan
Tirofiban is a non-peptide glycoprotein IIb/IIIa (αIIbβ3 integrin) receptor antagonist that blocks the binding of fibrinogen, von Willebrand factor, and other adhesive proteins to activated platelet receptors, preventing platelet aggregation and thrombus formation. It is used intravenously in combination with heparin for the management of acute coronary syndromes (unstable angina and NSTEMI) and percutaneous coronary intervention. Its reversible binding and short duration of action allow rapid recovery of platelet function after discontinuation.
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Yes, Tirofiban is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL916. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 60947. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="tirofiban"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/tirofiban/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/tirofiban/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/tirofiban/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="tirofiban"></drugfyi-drug>